In this context, Das et al. demonstrated that melanoma patients had a decline in the overall number of circulating B cells after combined ICI treatments (i.e., anti-CTLA4 and anti PD1/PD-L1), along with an increase in CD21low B cells and plasmablasts, which also correlated with an increase in the risk of irAE development [59]. This evidence concerns the gene CTLA4 and melanoma.